Funded into 2030, running alone in chronic cough
- Trevi has no approved products and no commercial revenue today.
- Its whole story rests on Haduvio, an oral extended-release form of nalbuphine.
- The company recently started two Phase 3 trials in IPF-related chronic cough.
- Two rival drugs failed recently, leaving Trevi alone in its targeted markets.
- With about $299 million in cash, the company expects its funding to last into 2030.
A cleared field and a clear path
Trevi is now fully in execution mode. The company recently started both of its pivotal Phase 3 trials for Haduvio in IPF-related chronic cough. It also aligned with the FDA on the path forward for non-IPF ILD, setting up another trial to start in early 2027.
The biggest recent change is the competitive landscape. Two rival chronic cough drugs failed over the summer. This leaves Trevi as the only company pursuing these specific cough markets. The bull case is stronger now because a crowded race has turned into a potential monopoly if Haduvio wins approval.
The financial picture remains strong. With about $299 million in cash as of late 2026, management expects to fund operations into 2030. This covers the critical clinical readouts without needing to sell more stock.
However, the bear case is tied strictly to clinical and commercial execution. Haduvio must prove it works where others failed. Also, management plans to keep global rights rather than partnering. This means Trevi will have to build its own sales team from scratch if the drug is approved.
No sales yet, one future product
Trevi does not make money from product sales today. It is spending investor capital to test Haduvio in several types of chronic cough. The business only works if Haduvio wins approval, doctors prescribe it, and payers agree to cover it.
Haduvio is oral nalbuphine ER, meaning an extended-release pill form of nalbuphine. Trevi believes its central and peripheral action could help calm abnormal cough signaling. That is the main scientific reason for the company to exist.
The model is high risk but easy to understand. Clinical data create value, failed trials destroy value, and future profits would require Trevi to build a commercial sales effort alone. Keeping global rights means the company keeps all potential profits but takes on all the launch costs.
One drug, several shots
Haduvio first IPF Phase 3 trial
The OCEAN-1 trial is a 52-week study with the main efficacy check at 24 weeks. This trial is the first major test of whether Phase 2 cough results can hold up in a larger study.
Haduvio second IPF Phase 3 trial
The OCEAN-2 trial is a 12-week confirmatory study. Success in both trials would be central to a possible FDA approval package.
Haduvio for refractory chronic cough
Trevi is running a Phase 2b dose-ranging study called LAKE. An interim update to check the required sample size is due in early 2027.
Haduvio for non-IPF ILD chronic cough
After aligning with the FDA, Trevi plans to start a Phase 2 study in early 2027 to widen Haduvio beyond IPF lung scarring diseases.
A single development company
Trevi reports as a clinical-stage company with no commercial products. For this page, the mix reflects the late 2026 financial context: essentially all economic exposure is Haduvio development, while commercial product revenue is zero.
What could break
Phase 3 IPF failure
High impact · Medium oddsThe main value driver is Haduvio in IPF-related chronic cough. If the primary cough endpoints miss in the new OCEAN trials, Trevi would have few other ways to support its valuation.
Single-product dependence
High impact · High oddsTrevi has one drug candidate. The company is testing it in several cough settings, but those programs still depend on the same molecule. A safety or regulatory problem with Haduvio would hit the whole company.
Launch buildout risk
Medium impact · Medium oddsTrevi plans to retain global rights rather than partnering with a larger pharmaceutical company. Building a specialized sales and marketing infrastructure from scratch will present major operational and financial challenges.
Refractory chronic cough trial sizing
Medium impact · Medium oddsThe ongoing LAKE Phase 2b trial will have an interim sample size check. If the trial is expanded significantly, it could suggest a smaller drug effect or higher variability than hoped.
In one breath
Does Trevi Therapeutics have any approved drugs?
No. Trevi is a clinical-stage biotech, so it does not have approved products or commercial product revenue today. Its only drug candidate is Haduvio.
What is Haduvio being tested for?
Haduvio is being tested for chronic cough in IPF, refractory chronic cough, and chronic cough in non-IPF ILD. The lead program is currently in Phase 3 trials.
What is the biggest near-term thing to watch?
Investors should watch the interim sample size update for the LAKE trial in early 2027, followed by top-line results from the Phase 3 IPF trials later on.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Trevi Therapeutics, Inc. in Finn's Biotechnology industry ranking.

